Format

Send to

Choose Destination
Drugs. 2016 Jul;76(11):1135-45. doi: 10.1007/s40265-016-0602-3.

Secukinumab: A Review in Psoriatic Arthritis.

Author information

1
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
2
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.

Abstract

Secukinumab (Cosentyx(®)) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. It is the first-in-class anti-IL-17 agent, initially approved for the treatment of plaque psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis. This article reviews the therapeutic efficacy of subcutaneous secukinumab in the treatment of psoriatic arthritis, as well as discussing the tolerability and pharmacological properties of the drug. Phase III clinical trial data demonstrated that, compared with placebo, subcutaneous secukinumab was efficacious in improving the signs and symptoms of psoriatic arthritis in patients with active disease despite previous treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs). In addition, secukinumab treatment was associated with significant improvements in patient-reported measures of physical functioning and health-related quality of life. Secukinumab is generally well tolerated, with the most common adverse events being mild to moderate, non-serious infections, such as upper respiratory tract infections and nasopharyngitis. In conclusion, although longer-term and comparative data are lacking, current clinical data indicate that secukinumab is efficacious and well tolerated in the treatment of psoriatic arthritis, and it thus provides a useful treatment alternative to tumour necrosis factor inhibitors and other targeted DMARDs.

PMID:
27299434
DOI:
10.1007/s40265-016-0602-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center